Mevion Wins FDA Clearance for MEVION S250-FIT™ Proton Therapy System
Mevion Medical Systems has received 510(k) clearance from the US Food and Drug Administration (FDA) for its MEVION S250-FIT™ Proton Beam Radiation Therapy System.
The approval marks a key step in widening access to advanced proton therapy.
The MEVION S250-FIT™ is the first proton therapy system designed to fit into a standard radiation therapy vault, allowing hospitals and cancer centres to use existing infrastructure.
This approach aims to reduce installation costs and make proton therapy more accessible to patients worldwide.
The system is already being installed at Stanford Health Care and BayCare Health System, with further installations planned at Atlantic Health System and the University of Nebraska Medical Center.
The growing adoption by leading institutions highlights the system’s potential to accelerate the availability of proton therapy.
The S250-FIT™ extends Mevion’s portfolio of compact proton therapy systems, combining its HYPERSCAN® pencil beam scanning platform with new DirectArc™ proton arc therapy.
It is also prepared for FLASH research, enabling cancer centres to access cutting-edge capabilities while remaining ready for future advances.